Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone + UDCA in PBC with Moderate to Severe Interface Hepatitis
NCT06591468Phase 3Enrolling by invitation
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of prednisone in primary biliary cholangitis (PBC) (2 arms). Primary endpoint: Percentage of patients with biochemical response at 1 year. Started Oct 2024; status: enrolling by invitation.
02
Drugs
prednisone
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06591468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591468.